These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 26096750)

  • 1. Regulation Policy for Cell and Tissue Therapies in Australia.
    Sturm M
    Tissue Eng Part A; 2015 Dec; 21(23-24):2797-801. PubMed ID: 26096750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raising the standard: changes to the Australian Code of Good Manufacturing Practice (cGMP) for human blood and blood components, human tissues and human cellular therapy products.
    Wright C; Velickovic Z; Brown R; Larsen S; Macpherson JL; Gibson J; Rasko JE
    Pathology; 2014 Apr; 46(3):177-83. PubMed ID: 24614714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of cellular therapy in Australia.
    Trickett AE; Wall DM
    Pathology; 2011 Oct; 43(6):627-34. PubMed ID: 21897330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of cellular therapies: the Australian perspective.
    Wall DM; Prince HM
    Cytotherapy; 2003; 5(4):284-8. PubMed ID: 12944233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of Cell- and Tissue-Based Therapeutic Products in Singapore.
    Kellathur SN
    Tissue Eng Part A; 2015 Dec; 21(23-24):2802-5. PubMed ID: 26096855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Translation of Cell Therapy, Tissue Engineering, and Regenerative Medicine Product in Malaysia and Its Regulatory Policy.
    Bt Hj Idrus R; Abas A; Ab Rahim F; Saim AB
    Tissue Eng Part A; 2015 Dec; 21(23-24):2812-6. PubMed ID: 26192075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of the Therapeutic Goods Administration and the Medicine and Medical Devices Safety Authority in evaluating complementary and alternative medicines in Australia and New Zealand.
    Ghosh D; Skinner M; Ferguson LR
    Toxicology; 2006 Apr; 221(1):88-94. PubMed ID: 16481089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Premarket Regulation of Tissue Engineered Medical Products in China.
    Wang C; Wang A; Feng X; Ke L; Huang Y; Han Q; Sun X; Yang Z
    Tissue Eng Part A; 2015 Dec; 21(23-24):2806-11. PubMed ID: 26529310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. History of regulatory requirements for poultry biologics in the United States, 1970s to 1990s.
    Espeseth DA; Lasher H
    Avian Dis; 2013 Jun; 57(2):167-71. PubMed ID: 24689169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation Policy on Cell- and Tissue-Based Therapy Products in Korea.
    Lim JO
    Tissue Eng Part A; 2015 Dec; 21(23-24):2791-6. PubMed ID: 25759938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent legal developments and the authority of the Australian Therapeutic Goods Administration.
    Shirlow E; Faunce T
    J Law Med; 2009 May; 16(5):764-9. PubMed ID: 19554858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and Future Cell Therapy Standards and Guidelines.
    Atkins JW; West K; Kasow KA
    Hematol Oncol Clin North Am; 2019 Oct; 33(5):839-855. PubMed ID: 31466608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards a common framework for defining ancillary material quality across the development spectrum.
    Ball O; Zylberberg C
    Cytotherapy; 2019 Dec; 21(12):1234-1245. PubMed ID: 31837736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of Regenerative Medicine Products.
    Gee AP
    Adv Exp Med Biol; 2018; 1098():189-198. PubMed ID: 30238372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Four Food and Drug Administration draft guidance documents and the REGROW Act: A litmus test for future changes in human cell- and tissue-based products regulatory policy in the United States?
    Yano K; Speidel AT; Yamato M
    J Tissue Eng Regen Med; 2018 Jul; 12(7):1579-1593. PubMed ID: 29702746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Requirements for Foreign and Domestic Establishment Registration and Listing for Human Drugs, Including Drugs That Are Regulated Under a Biologics License Application, and Animal Drugs. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2016 Aug; 81(169):60169-224. PubMed ID: 27580511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of manufacture--principles and purposes.
    Luff PR
    Dev Biol Stand; 1992; 79():155-8. PubMed ID: 1286749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The emergence and popularisation of autologous somatic cellular therapies in Australia: therapeutic innovation or regulatory failure?
    McLean AK; Stewart C; Kerridge I
    J Law Med; 2014 Sep; 22(1):65-89. PubMed ID: 25341320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of gene therapy products and the impact of manufacturing changes on product comparability.
    Simek SL
    Dev Biol (Basel); 2005; 122():139-44. PubMed ID: 16375258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early history of regulatory requirements for poultry biologics in the United States.
    Espeseth DA; Lasher H
    Avian Dis; 2010 Dec; 54(4):1136-43. PubMed ID: 21313831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.